Article
IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
Oncotarget - 7 Jun 2016
Shekhar Tanmay M, Miles Mark A, Gupte Ankita, Taylor Scott, Tascone Brianna, Walkley Carl R, Hawkins Christine J
Abstract excerpt
Outcomes for patients diagnosed with the bone cancer osteosarcoma have not improved significantly in the last four decades. Only around 60% of patients and about a quarter of those with metastatic disease survive for more than five years. Although DNA-damaging chemotherapy drugs can be effective, they can provoke serious or fatal adverse effects including cardiotoxicity and therapy-related cancers. Better and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.